The Immune Assessment of PD-1 Antibody Therapy in Tumor
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorQuanli Gao
About this trial
This retrospective study will leverage previous immune function monitoring results in conjunction with clinical case data at this medical center.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥18 years.
Pathologically confirmed malignant tumors.
Complete medical records.
Assessable immune function test data.
Disqualifiers
Age <18 years.
No confirmed tumor pathology.
Untraceable medical records.
Non-assessable immune function tests.
Trial population
Adult patients with cancer
Trial design
Design model
Case-control
Time perspective
Retrospective
Treatments tested in this trial
PD-1 Inhibitors
DrugPatients received PD-1 inhibitors mono- or combined therapy in real-world clinical practice
Treatment groups
3,000 Participants
are divided into 2 treatment groupsGroup A: Experimental group1 intervention
Group B: Control group1 intervention
Trial outcomes
Primary outcomes
1
Objective response rate
The objective response rate at 6 months
Time frame
6 months2
Adverse events
Number of participants who experienced immune-related adverse events at 1 year according to CTCAE 5.0
Time frame
1 yearSecondary outcomes
1
Overall survival
The overall survival rate at 1 year
Time frame
1 yearOther outcomes
1
Duration of response
The duration of response at 2-year
Time frame
2 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Quanli Gao
Lead sponsor
Henan Cancer Hospital
Sponsor institution
Source ClinicalTrials.gov